Related references
Note: Only part of the references are listed.Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder
Ioannis Boulalas et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2017)
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers
Igor Makhlin et al.
BJU INTERNATIONAL (2011)
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
Edmund Chiong et al.
CLINICAL CANCER RESEARCH (2011)
K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder
Imran Ahmad et al.
DISEASE MODELS & MECHANISMS (2011)
Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex
Stefanie Anderl et al.
HUMAN MOLECULAR GENETICS (2011)
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
J. P. Robinson et al.
ONCOGENE (2011)
Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
Donna E. Hansel et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
The Insulin-Like Growth Factor Receptor I Promotes Motility and Invasion of Bladder Cancer Cells through Akt- and Mitogen-Activated Protein Kinase-Dependent Activation of Paxillin
David Metalli et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes
Xiaofeng Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Expression Status and Prognostic Significance of Mammalian Target of Rapamycin Pathway Members in Urothelial Carcinoma of Urinary Bladder After Cystectomy
Luciana Schultz et al.
CANCER (2010)
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)
Courtney Pollard et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2010)
Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features
Kurt B. Hodges et al.
HUMAN PATHOLOGY (2010)
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
Christina Barbara Ching et al.
LABORATORY INVESTIGATION (2010)
Genomic instability - an evolving hallmark of cancer
Simona Negrini et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation
J. P. Robinson et al.
ONCOGENE (2010)
Diagnostic random bladder biopsies: Reflections from a population-based cohort of 538 patients
Andreas Thorstenson et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2010)
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
Peter J. Goebell et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Molecular pathways of urothelial development and bladder tumorigenesis
Mireia Castillo-Martin et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
David J. McConkey et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Molecular Pathogenesis and Diagnostics of Bladder Cancer
Anirban P. Mitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Key Concerns About the Current State of Bladder Cancer A Position Paper From the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology
Yair Lotan et al.
CANCER (2009)
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Margaret A. Knowles et al.
CANCER AND METASTASIS REVIEWS (2009)
Biology of urothelial tumorigenesis: insights from genetically engineered mice
Xue-Ru Wu
CANCER AND METASTASIS REVIEWS (2009)
Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARγ/RXR Heterodimers to Activate the Intrinsic Death Pathway by NO
Pattabhiraman Shankaranarayanan et al.
CANCER CELL (2009)
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Fiona M. Platt et al.
CLINICAL CANCER RESEARCH (2009)
Inactivation of p53 and Pten promotes invasive bladder cancer
Anna M. Puzio-Kuter et al.
GENES & DEVELOPMENT (2009)
Generation of a Concise Gene Panel for Outcome Prediction in Urinary Bladder Cancer
Anirban P. Mitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Pankaj P. Dangle et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
The present and future burden of urinary bladder cancer in the world
Martine Ploeg et al.
WORLD JOURNAL OF UROLOGY (2009)
Ras Signaling Influences Permissiveness of Malignant Peripheral Nerve Sheath Tumor Cells to Oncolytic Herpes
Faris Farassati et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival
Chun-Liang Chen et al.
MOLECULAR CANCER (2008)
An oncogene-induced DNA damage model for cancer development
Thanos D. Halazonetis et al.
SCIENCE (2008)
Label-retaining cells of the bladder: candidate urothelial stem cells
Eric A. Kurzrock et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study
P. K. Tsantoulis et al.
ONCOGENE (2008)
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
Margaret A. Knowles
WORLD JOURNAL OF UROLOGY (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
p53: Guardian of the genome and policeman of the oncogenes
Alejo Efeyan et al.
CELL CYCLE (2007)
The management of superficial bladder cancer
Guido Dalbagni
NATURE CLINICAL PRACTICE UROLOGY (2007)
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng et al.
BLOOD (2007)
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis
Lan Mo et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder
Johanna M. M. van Oers et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
MA Knowles
CARCINOGENESIS (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation
D Ahuja et al.
ONCOGENE (2005)
Mechanisms of disease: genetic and EPIGENETIC alterations that drive bladder cancer
EM Wolff et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans
A Logié et al.
HUMAN MOLECULAR GENETICS (2005)
Radical cystectomy for bladder cancer: The case for early intervention
SS Chang et al.
UROLOGIC CLINICS OF NORTH AMERICA (2005)
Urothelial tumorigenesis: A tale of divergent pathways
XR Wu
NATURE REVIEWS CANCER (2005)
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
BSW van Rhijn et al.
CANCER RESEARCH (2004)
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer
SF Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis
J Gao et al.
ONCOGENE (2004)
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer
SJ Chatterjee et al.
JOURNAL OF PATHOLOGY (2004)
Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification
JS Aveyard et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2004)
Comparative pathology of proliferative lesions of the urinary bladder
SM Cohen
TOXICOLOGIC PATHOLOGY (2002)
The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network
LD Mayo et al.
TRENDS IN BIOCHEMICAL SCIENCES (2002)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
The INK4a/ARF network in tumour suppression
CJ Sherr
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Immunosuppressant rapamycin inhibits protein kinase C α and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis
CD Oh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
K Podsypanina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Simian virus 40 large tumor antigen modulates the Raf signaling pathway
N Grammatikakis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation
ZT Zhang et al.
ONCOGENE (2001)
Mutation of cell cycle regulators and their impact on superficial bladder cancer
F Rabbani et al.
UROLOGIC CLINICS OF NORTH AMERICA (2000)
Share Paper
